Nordson Corporation (NASDAQ:NDSN) Q1 2024 Results Earnings Conference Call February 22, 2024 8:00 AM ET Company Participants Lara Mahoney - Vice President of Investor Relations and Corporate Communications Sundaram Nagarajan - President and Chief Executive Officer Stephen Shamrock - Vice President, Corporate Controller and Interim Chief Financial Officer Conference Call Participants Matt Summerville - D.A. Davidson & Co. Allison Poliniak-Cusic - Wells Fargo Securities Saree Boroditsky - Jefferies Michael Ha ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-7977 NORDSON CORPORATION (Exact name of registrant as specified in its charter) ________________________________________________ ...

Nordson Corporation Reports First Quarter Fiscal 2024 Results and Narrows Annual Guidance Guidance: • Narrowing previously issued full-year fiscal 2024 revenue guidance to 4% to 7% growth over record fiscal 2023 and adjusted earnings per diluted share to the range of $10.00 to $10.50 per share WESTLAKE, Ohio--(BUSINESS WIRE)--February 21, 2024--Nordson Corporation (Nasdaq: NDSN) today reported results for the fiscal first quarter ended January 31, 2024. Sales were $633 million, a 4% increase compared to the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended October 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-7977 NORDSON CORPORATION (Exact name of Registrant as specified in its charter) Ohio (State of incorporation) 28601 Clemens Road Westlak ...

Financial Data and Key Metrics Changes - Fourth quarter 2023 sales were $719 million, a 5% increase from $684 million in the prior year [8] - EBITDA for the fourth quarter increased 12% to a record $227 million, or 32% of sales, compared to $202 million or 30% of sales in the prior year [21] - Net income totaled $128 million or $2.22 per share, with adjusted earnings per share of $2.46, a 1% increase over the prior year [23] - Full year EBITDA increased 1% to a record $819 million, or 31% of sales, marking the third consecutive year of EBITDA growth [24] Business Line Data and Key Metrics Changes - Industrial Precision Solutions sales increased 14% to $405 million, with organic growth of 4% and ARAG acquisition contributing 7% [36] - Advanced Technology Solutions sales decreased 1% to $145 million, with a 16% organic sales volume decline offset by a 15% contribution from CyberOptics [37] - Medical and Fluid Solutions sales decreased 7% to $169 million, primarily due to an 8% organic sales volume decline [59] Market Data and Key Metrics Changes - Strong growth was noted in the Americas and Asia Pacific regions, with EBITDA for the quarter at $148 million, or 37% of sales, a 26% increase from the prior year [25] - The electronics division is positioned for incremental earnings growth as the semiconductor market is expected to recover in the second half of calendar 2024 [28] Company Strategy and Development Direction - The company aims to achieve $3 billion in sales and greater than 30% EBITDA margins by 2025 as part of its Ascend strategy [6] - The Ascend strategy has led to solid financial performance, with record sales and cash flow in fiscal 2023 [7] - The company is focused on acquiring differentiated precision technologies to enhance its portfolio and meet strategic and financial criteria [62] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate economic uncertainties, citing a strong focus on customers and innovation [61] - The biopharma market is expected to recover to high single-digit growth rates, with no structural impediments identified [44] - For fiscal 2024, sales are forecasted to grow between 4% to 9% above fiscal 2023 sales, with adjusted earnings growth of 1% to 8% per diluted share [63] Other Important Information - The company generated a record free cash flow of $607 million for the full year 2023, allowing for debt repayment and shareholder returns [26] - The integration of the ARAG acquisition is progressing well, with expectations for continued growth in the European and South American markets [118] Q&A Session Summary Question: How does the EBITDA margin evolve over the next two to three years? - Management believes the current EBITDA margin of 31% is sustainable, depending on the mix of organic and acquisition growth [42] Question: What is the expected cadence of recovery in the biopharma market? - Recovery is anticipated to be slower, with a return to high single-digit growth expected in the long term [43][44] Question: What is the organic growth assumption embedded in the guidance? - The full year guidance implies organic growth of about 1%, with a total growth forecast of 6% [52] Question: How is the electronics segment expected to recover? - Recovery is expected based on historical trends and customer conversations, with a good pipeline of opportunities [53] Question: What are the expectations for the ARAG business in 2024? - ARAG is expected to grow in 2024, despite some market pressures, due to its recurring revenue model [76]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-7977 NORDSON CORPORATION (Exact name of registrant as specified in its charter) ___________________________________________________ ...

Nordson Corporation (NASDAQ:NDSN) Q3 2023 Earnings Conference Call August 22, 2023 8:30 AM ET Company Participants Lara Mahoney - VP, IR & Corporate Communications Sundaram Nagarajan - President & CEO Joseph Kelley - EVP & CFO Conference Call Participants Jeff Hammond - KeyBanc Capital Markets Allison Poliniak - Wells Fargo Matt Summerville - D.A. Davidson Christopher Glynn - Oppenheimer Mike Halloran - Baird Operator Hello, and welcome to the Nordson Corporation's Third Quarter Fiscal Year 2023 Conference ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-7977 NORDSON CORPORATION (Exact name of registrant as specified in its charter) __________________________________________________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2023 (State or other jurisdiction of incorporation or organization) 28601 Clemens Road Westlake, Ohio (Address of principal executive offices) 34-0590250 (I.R.S. Employer Identification No.) 44145 (Zip Code) (440) 892-1580 (Registrant's Telephone Number, Including Area Code) Securities ...

Nordson Corporation (NASDAQ:NDSN) Q4 2022 Earnings Conference Call December 15, 2022 8:30 AM ET Company Participants Sundaram Nagarajan - President, Chief Executive Officer Joe Kelley - Executive Vice President, Chief Financial Officer Lara Mahoney - Vice President, Investor Relations Conference Call Participants Matt Summerville - DA Davidson Mike Halloran - Baird Allison Poliniak - Wells Fargo Jeff Hammond - Keybanc Capital Markets Connor Lynagh - Morgan Stanley Christopher Glynn - Oppenheimer Operator ...